Clinical trial

BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients

NCT03394989

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Fluticasone propionate/salmeterol 100/50 µg Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT Normalized identity: 60 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler [Advair]View linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-10-17

PhasePHASE3

Conditions

Bronchial Asthmaunresolved

Interventions

Fluticasone propionate/salmeterol 100/50 µgDRUG

PlaceboOTHER

Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUATDRUG · verified · RxNorm: 60 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler [Advair]

Sponsors & collaborators

Cipla Ltd.lead sponsor

Mapped research locations

OrlandoFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03394989 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.